A retrospective pharmacovigilance observational disproportionality study based on VigiBase- to identify and characterize immune checkpoint inhibitors-associated pituitary adverse events

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Ovarian cancer; Pituitary cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions

08 Apr 2020 New trial record
01 Apr 2020 Results published in the Journal of Endocrinological Investigation

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com